See more : Bank of Communications Co., Ltd. (BCMXY) Income Statement Analysis – Financial Results
Complete financial analysis of Bellicum Pharmaceuticals, Inc. (BLCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bellicum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Braime Group PLC (BMTO.L) Income Statement Analysis – Financial Results
- CleanTech Acquisition Corp. (CLAQW) Income Statement Analysis – Financial Results
- Environmental Waste International Inc. (YEWTF) Income Statement Analysis – Financial Results
- ERecord Management, Inc. (ERMG) Income Statement Analysis – Financial Results
- Redeia Corporación, S.A. (REE.VI) Income Statement Analysis – Financial Results
Bellicum Pharmaceuticals, Inc. (BLCM)
About Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.50M | 6.20M | 500.00K | 7.14M | 1.12M | 185.00K | 388.00K | 282.00K | 1.78M | 1.94M | 1.47M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.50M | 6.20M | 500.00K | 7.14M | 1.12M | 185.00K | 388.00K | 282.00K | 1.78M | 1.94M | 1.47M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 22.76M | 23.58M | 39.05M | 64.54M | 71.15M | 65.66M | 51.26M | 33.56M | 11.01M | 7.05M | 5.80M |
| General & Administrative | 5.72M | 7.01M | 15.53M | 29.97M | 25.43M | 21.91M | 17.51M | 15.86M | 5.40M | 2.81M | 1.94M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.72M | 7.01M | 15.53M | 29.97M | 25.43M | 21.91M | 17.51M | 15.86M | 5.40M | 2.81M | 1.94M |
| Other Expenses | 0.00 | 7.00K | 112.00K | -2.99M | 436.00K | 864.00K | 580.00K | 3.18M | 43.21B | 0.00 | 0.00 |
| Operating Expenses | 28.48M | 30.59M | 54.58M | 94.51M | 96.59M | 87.57M | 68.77M | 49.42M | 16.41M | 9.86M | 7.74M |
| Cost & Expenses | 28.48M | 30.59M | 54.58M | 94.51M | 96.59M | 87.57M | 68.77M | 49.42M | 16.41M | 9.86M | 7.74M |
| Interest Income | 0.00 | 32.00K | 387.00K | 1.35M | 1.64M | 1.06M | 909.00K | 641.00K | 34.98K | 3.92K | 7.55K |
| Interest Expense | 46.00 | 4.00K | 2.66M | 4.28M | 4.20M | 3.67M | 1.76M | 12.00K | 1.76M | 50.72K | 1.41K |
| Depreciation & Amortization | -1.95M | 517.00K | -1.89M | 19.19M | 6.70M | 3.56M | 2.31M | 1.20M | 666.61K | 587.25K | 115.28K |
| EBITDA | -26.98M | -24.35M | 2.39M | -87.36M | -95.47M | -82.77M | -68.38M | -47.30M | -57.84B | -7.33M | -6.15M |
| EBITDA Ratio | -1,928.93% | -392.73% | -10,716.80% | -954.39% | -8,523.75% | -44,739.46% | -17,623.71% | -16,771.28% | -821.69% | -377.75% | -418.02% |
| Operating Income | -26.98M | -24.87M | -51.69M | -87.36M | -95.47M | -87.39M | -68.38M | -49.14M | -57.84M | -7.92M | -6.27M |
| Operating Income Ratio | -1,798.73% | -401.06% | -10,338.40% | -1,223.07% | -8,523.75% | -47,236.22% | -17,623.71% | -17,423.76% | -3,249.33% | -408.21% | -426.37% |
| Total Other Income/Expenses | 2.01M | 15.16M | -10.11M | -25.11M | -2.57M | -4.39M | -861.00K | 587.00K | -26.13M | -46.80K | 6.14K |
| Income Before Tax | -24.97M | -9.71M | -7.72M | -112.48M | -98.04M | -91.78M | -69.24M | -48.55M | -83.97M | -7.97M | -6.26M |
| Income Before Tax Ratio | -1,664.73% | -156.53% | -1,544.40% | -1,574.65% | -8,753.21% | -49,610.27% | -17,845.62% | -17,215.60% | -4,717.13% | -410.62% | -425.96% |
| Income Tax Expense | 2.00K | -127.00K | 897.00K | 13.62M | 1.63M | 3.67M | -1.46M | 12.00K | 1.09M | 3.92K | 7.55K |
| Net Income | -24.97M | -9.58M | -8.62M | -126.09M | -98.04M | -91.78M | -69.24M | -48.55M | -83.97M | -7.97M | -6.26M |
| Net Income Ratio | -1,664.87% | -154.48% | -1,723.80% | -1,765.25% | -8,753.21% | -49,610.27% | -17,845.62% | -17,215.60% | -4,717.13% | -410.62% | -425.96% |
| EPS | -0.81 | -0.83 | -1.50 | -26.92 | -24.37 | -28.94 | -25.69 | -18.43 | -33.47 | -8.11 | -6.37 |
| EPS Diluted | -0.81 | -0.83 | -1.50 | -26.92 | -24.37 | -28.94 | -25.69 | -18.43 | -33.47 | -8.11 | -6.37 |
| Weighted Avg Shares Out | 30.83M | 11.50M | 5.76M | 4.68M | 4.02M | 3.17M | 2.70M | 2.63M | 2.51M | 982.78K | 982.78K |
| Weighted Avg Shares Out (Dil) | 30.83M | 11.50M | 5.76M | 4.68M | 4.02M | 3.17M | 2.70M | 2.63M | 2.51M | 982.78K | 982.78K |
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid...
Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?
Here is how Bellicum Pharmaceuticals (BLCM) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 45,000, as previously stated. The corrected release follows:
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation...
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead...
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) team...
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on...
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment...
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2022 and provided an operational update.
Source: https://incomestatements.info
Category: Stock Reports